Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBIT (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of EBIT readings, the most recent being -$11.3 million for Q4 2025.

  • On a quarterly basis, EBIT rose 52.2% to -$11.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$73.1 million, a 33.79% increase, with the full-year FY2025 number at -$85.3 million, up 29.86% from a year prior.
  • EBIT hit -$11.3 million in Q4 2025 for Enanta Pharmaceuticals, up from -$18.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$11.3 million in Q4 2025 to a low of -$39.5 million in Q1 2023.
  • Median EBIT over the past 5 years was -$30.2 million (2021), compared with a mean of -$28.8 million.
  • Biggest five-year swings in EBIT: crashed 150.11% in 2021 and later skyrocketed 52.2% in 2025.
  • Enanta Pharmaceuticals' EBIT stood at -$30.4 million in 2021, then rose by 1.3% to -$30.0 million in 2022, then fell by 16.24% to -$34.9 million in 2023, then surged by 32.51% to -$23.5 million in 2024, then skyrocketed by 52.2% to -$11.3 million in 2025.
  • The last three reported values for EBIT were -$11.3 million (Q4 2025), -$18.4 million (Q3 2025), and -$18.9 million (Q2 2025) per Business Quant data.